CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 7059 result(s)

CADTH Provisional Funding Algorithms

Published on: December 2, 2020
Result type: General Content

1. About Provisional Funding Algorithms  The provisional algorithm process is used to provide advice to drug programs when they have indicated that there is need to establish an appropriate place in therapy for new oncology drugs relative to alternative treatments that are currently reimbursed by the drug programs. The process ascertains t...

Internet-Delivered Cognitive Behavioural Therapy for Chronic Pain

Last Updated: December 2, 2020
Result type: Reports
Product Line: Rapid Response

Pain is recognized as a complex, multi-dimensional condition that is characterized by an interplay of biological, psychological, and social factors. Current recommendations and strategies to address pain emphasize the need for multi-disciplinary approaches that encompass physical and psychological therapies and other interventions to target the ...

  • Project Number: DE0075-000

Levetiracetam (pdp-levETIRAcetam)

Last Updated: November 27, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Levetiracetam
Indications: Adjunctive therapy for: Adults management of patients with epilepsy who are not satisfactorily controlled by conventional therapyPediatrics partial onset seizures with or without secondary generalization in adolescents, children and infants from 1 month of age with epilepsy. myoclonic seizures in adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. primary generalized tonic-clonic seizures in adolescents from 12 years of age with Idiopathic Generalized Epilepsy.

  • Brand Name: pdp-levETIRAcetam
  • Manufacturer: Pendopharm, a division of Pharmascience Inc.
  • Project Number: SR0653-000
  • Project Status: Active
  • Submission Type: Initial

onasemnogene abeparvovec (Zolgensma)

Last Updated: November 27, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: onasemnogene abeparvovec
Indications: ​Zolgensma is an adeno-associated virus (AVV) vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.

  • Brand Name: Zolgensma
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SG0649-000
  • Project Status: Active
  • Submission Type: Initial

voretigene neparvovec (Luxturna)

Last Updated: November 30, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: voretigene neparvovec
Indications: ​Indicated for the treatment of adult and pediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.

  • Brand Name: Luxturna
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SG0643-000
  • Project Status: Active
  • Submission Type: Initial